Initial clinical observations suggest high level of T cells reprogramming and CAR-T expansion at the starting dose without lymphodepletion At 28 ...

Researchers developed a dual-vector "zip-sorting" system, doubling the genetic capacity of CAR T cells to combat tumor ...

Physician-researchers with City of Hope have developed a way to add features to T cells to help them overcome mechanisms of chimeric antigen receptor (CAR) T cell therapy resistance. Their new system ...

To address this gap, researchers analyzed gene expression within individual tumor cells. This study reports the molecular features and interactions of tumor and immune cells associated with two ...

TCA-101 is under clinical development by TCR Cure Biopharma Technology and currently in Phase II for Solid Tumor.

For the first time, researchers have used lab-grown organoids created from tumors of individuals with glioblastoma (GBM) to accurately model a patient's response to CAR T cell therapy in real time.

CAR T cell therapy has revolutionized cancer care, providing a powerful option ... due to limited DNA packaging capacity of current vector systems,” said Scott E. James, M.D., Ph.D., assistant ...

Mu-28ZT2 is under clinical development by Wellington Zhaotai Therapies and currently in Phase I for Lung Cancer.

The researchers created organoids from the tumors of patients with recurrent glioblastoma who underwent surgery as part of a Phase I clinical trial for a dual-target CAR-T cell therapy.